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Abstract  
Purpose 
The objective of this study was to assess the value of fluorescence in situ hybridization (FISH) for 
predicting early recurrence in intermediate-, and high-risk NMIBC patients treated with BCG.  
 
Materials and methods 
A systematic review was conducted using MEDLINE, Embase and the Cochrane library. Individual 
patient data (IPD) from prospective observational studies evaluating FISH in patients treated with 
BCG were included. A two-stage IPD meta-analysis was carried out to assess the value of FISH for 
predicting tumor recurrence after BCG induction therapy. 
 
Results 
From four studies IPD were obtained of 422 patients, and 408 patients included in final analysis with 
a median follow-up of 18.8 months. The hazard ratio for recurrence when FISH was positive was pre-
BCG (t0) 1.20 (95% CI: 0.81–1.79), at six weeks (t1) 2.23 (95% CI: 1.31–3.62), at three months (t2) 3.70 
(95% CI: 2.34 – 5.83), and at six months (t3) 23.44 (95% CI: 5.26–104.49). 
 
Conclusion 
A positive FISH test post-BCG correlates with a higher risk for a tumor recurrence. FISH could aid 
urologists in risk stratification and counseling of patients. Based on both HR and its narrowest CI, the 
preferred timing for FISH is three months following TURBT. This is also in time for patients who fail to 
respond to induction therapy to enter clinical trials, or to change treatment strategy.  
 
Key words 
Urinary bladder neoplasms; mycobacterium bovis; in situ hybridization, fluorescence; recurrence; 
meta-analysis 
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Introduction 
Intravesical Bacillus Calmette-Guérin (BCG) is recommended by international guidelines for 
treatment of intermediate-, and high-risk non-muscle invasive bladder cancer (NMIBC).
1–4
 
However, up to 40% of patients develop a recurrence despite BCG therapy and are exposed to the 
risk of progression as well as to its local and systemic side effects.
5–9
 Early identification of 
recurrence could minimize these risks and other treatment options can be considered at an 
earlier stage.  
Currently, follow-up of high-risk tumors is recommended with cystoscopy and urinary 
cytology. Cytology has a high sensitivity for grade 3 (high-grade) tumors, but a low sensitivity in grade 
1 (low-grade) tumors. However, BCG treatment can hamper cytological evaluation, and is therefore 
less reliable after BCG therapy.
10,11
 The UroVysion® fluorescence in situ hybridization (FISH) test 
detects chromosomal aberrations, associated with bladder cancer, and is not influenced by the BCG-
induced inflammatory response.
12,13
 In patients receiving BCG, several small studies have described a 
positive role of FISH in predicting recurrence following BCG instillations. To obtain more convincing 
evidence, we performed a systematic review and meta-analysis of individual patient data (IPD) from 
available studies assessing the prognostic value of FISH following BCG instillations for NMIBC. 
 
Materials and methods 
Protocol and registration 
This systematic review and IPD meta-analysis was registered in the PROSPERO international 
prospective register of systematic reviews (registration number CRD42018077631), and is reported 
following the Preferred Reporting Items for Systematic Reviews and Meta-analysis of Individual 
Participant Data statement.
14
 Ethical approval was documented in the original publications of all 
studies. 
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Eligibility criteria and literature search 
All prospective observational studies that evaluated FISH for tumor recurrence in NMIBC patients 
treated with BCG therapy (induction with or without maintenance) were eligible. A systematic 
literature search was conducted using MEDLINE (via PubMed), Embase and the Cochrane library 
(including the Cochrane Database of Systematic reviews and the Cochrane Central Register of 
Controlled Trials), without restrictions. The search strategy, outlined in Supplemental table 1, was 
conducted on September 7, 2017 and updated on September 6, 2018. The reference lists of the 
included studies were examined for additional studies.  
 
Study selection and risk of bias 
Two independent investigators (EL, RV) screened all identified titles and abstracts. Full-text papers of 
all candidate studies were retrieved. These studies were reviewed (EL, RV) and disagreements about 
study inclusion were resolved by a third investigator (TdR). Risk of bias was assessed according to the 
Quality In Prognosis Studies tool (EL, RV).
15
 
 
IPD collection and data integrity 
IPD for all eligible clinical trials were requested on (1) baseline characteristics including patients 
demographics and clinico-pathological characteristics; (2) timing of FISH tests and their results; and 
(3) clinical outcome, including time to recurrence and histopathology of recurrence. Before pooling 
the data into a single database, the data of all included trials were carefully checked. Any 
discrepancies were discussed and resolved with the authors. 
 
Specification of outcomes and effect measures 
The value of FISH at different time points was evaluated for predicting tumor recurrence in patients 
treated with BCG. Recurrence was defined as a histologically proven bladder tumor. Its predictive 
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value for progression to muscle invasive disease (stage ≥T2) was a secondary outcome. FISH tests 
were considered positive according to the definition in the individual studies. In assessment of FISH 
tests, some studies considered tetraploid cells as normal and some studies considered them as 
aberrant cells. For this study, tetraploid cells were considered aberrant cells. In case the original 
study reported a negative FISH test despite the presence of tetraploid cells, the FISH test was 
considered positive in the current study when the definition of a positive FISH test was met due to 
the tetraploid cells.  
 
Synthesis methods 
IPD at baseline and during follow-up were collected from all participating studies. Patients lacking all 
cystoscopic follow-up data or missing all FISH evaluations were considered incomplete and were 
excluded from the analyses. Patient-, and disease-specific characteristics were explored across 
studies using descriptive statistics. Follow-up time was calculated as time since initial transurethral 
resection of the bladder tumor (TURBT) to date of histologically proven recurrence, or last follow-up. 
Fixed-effect two-stage IPD meta-analysis forest plots were calculated. Heterogeneity across 
studies was assessed with the Cochrane Q chi-squared test and Higgins I
2
. We assumed no clinical 
heterogeneity between studies concerning population, intervention and outcome. Therefore, we 
conducted fixed effect meta-analyses. Hazard ratios, including their respective 95% confidence 
intervals (95% CI) were calculated with Cox regression analysis. Positive predictive value (PPV) and 
negative predictive value (NPV) were calculated using 2x2 tables. For the time-to-event outcomes, 
including time to recurrence and time to disease progression, the starting point was the date of the 
initial TURBT. The two time-to-event outcomes were estimated by Kaplan-Meier analysis with 
recurrence or disease progression as the event. Patients who died of other causes prior to recurrence 
or progression were censored. The time-to-event distributions were compared using the log-rank 
test. For both the meta-analysis forest plots and Kaplan Meier analysis, a Landmark analysis was also 
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performed for which patients with a recurrence at or before the landmark were excluded. The 
different points in time when FISH was performed were considered as landmark. Exploratory 
subgroup analyses were conducted based on a-priori defined subgroups. All tests were two-sided 
using 0.05 as the significance level. All analyses were performed using Stata/MP version 15.1. 
 
Results 
Study selection and availability of IPD 
The systematic search (Figure 1), identified six eligible studies.
16–21
 For two studies, the principal 
investigators no longer had access to IPD.
16,18
 IPD were finally available for four cohort studies, 
resulting in a total of 422 patients.
17,19–21
  
 
Risk of bias within studies 
In general, risk of bias of all four studies was comparable, with low risks of bias except for study 
attrition and confounding. The risk of bias assessment is listed in Table 1.  
 
Study and patient characteristics 
The main characteristics of the included studies are summarized in Table 2. Fourteen patients were 
excluded from all analyses (1 missing follow-up data, 13 missing all FISH results), resulting in a total 
of 408 patients included in the final analysis. In Table 3 baseline and tumor characteristics are 
summarized. Median follow-up was 18.8 months (interquartile range [IQR] 10.2–28.0 months).  
 
Pooled analyses regarding recurrence 
Out of 408 patients, 141 patients (34.6%) developed a recurrence during follow-up. Median time 
from initial TURBT to recurrence was nine months (IQR 5–16 months). For five patients a tumor 
recurrence was reported in the original study, but only based on high-grade (grade 3) cytology. In the 
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current analysis these five patients were not scored as having a histologically proven tumor 
recurrence. Two studies considered tetraploid cells as normal and two studies considered tetraploid 
cells as aberrant cells. Nineteen negative FISH tests reported in the original studies showed tetraploid 
cells. For this analysis the tetraploid cells were considered aberrant, and the FISH test was considered 
positive when the definition of a positive FISH test was met (Table 2). Subsequently, 13 of these 19 
FISH tests met the definition of a positive FISH test and were considered positive.  
FISH results were collected at four different time points (t0: pre-BCG; t1: at the end of BCG 
induction at six weeks; t2: at three months after initial TURBT; t3: at six months after initial TURBT), 
although not all studies provided data at each of these time points (Supplemental Figure 1). FISH 
results and occurred conversions are displayed in Table 4 and 5. Evaluation of bladder recurrences 
was performed by cystoscopy followed by histological confirmation.  
 
Predictive value of FISH for recurrence 
The predictive value of FISH was determined for the different time points (t0, t1, t2 and t3). For t1, t2, 
and t3, landmark analyses were performed. 
At t0, FISH results were available for 374 patients. A recurrence occurred in 133 patients 
(35.6%; 43 FISH negative [30.3%], 90 FISH positive [38.8%]). A positive FISH at t0 was not associated 
with a higher risk for recurrence (HR 1.20, 95% CI: 0.81–1.79) (Figure 2A). Fixed-effect meta-analysis 
showed no heterogeneity (I
2
=28.0%, p=0.244).  PPV was 67.7%, and NPV was 69.7%. 
At t1, 249 FISH evaluations were available. In 84 patients (33.7%) a tumor recurrence 
occurred during follow-up (44 FISH negative [26.2%], 40 FISH positive [49.4%]). A positive FISH at t1 
was associated with a higher risk for recurrence (HR 2.23, 95% CI: 1.37–3.62) (Figure 2B). Meta-
analysis showed moderate heterogeneity (I
2
=51.3%, p=0.152). PPV and NPV were respectively 47.6% 
and 73.8%. 
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At t2, 303 FISH evaluations from all studies were available. In 103 patients (34.0%) a 
recurrence developed during further follow-up (35 FISH negative [18.8%], 68 FISH positive [58.1%]). 
A positive FISH at t2 was associated with a higher risk for recurrence (HR 3.70, 95% CI: 2.34–5.83) 
(Figure 2C). Meta-analysis showed no heterogeneity (I
2
=0.0%, p=0.676). PPV and NPV were 66.0% 
and 81.2%, respectively.  
At t3, 71 patients with FISH evaluations were available from one trial and in 19 patients 
(26.8%) a recurrence occurred during further follow-up (4 FISH negative [8.2%], 15 FISH positive 
[68.2%]). A positive FISH at t3 was associated with a higher risk for developing a recurrence (HR 
23.44, 95% CI: 5.26–104.49) (Figure 2D), though this should be interpreted with caution given the 
wide 95% CI. PPV was 78.9% and NPV was 91.8%. 
 
Analysis for recurrence-free survival 
Kaplan-Meier curves for the different time points are shown in Figure 3. For t1, t2, and t3 landmark 
analyses were performed. Log-rank test did not show an association between a positive FISH test 
pre-BCG (t0) and tumor recurrence (p=0.160). However, a positive FISH test following BCG induction 
therapy (t1, t2, or t3) was associated with a higher risk of tumor recurrence (all p<0.005).  
 
Predictive value of FISH for progression to muscle-invasive disease (T ≥2) 
Disease progression to muscle-invasive bladder cancer occurred in 17 patients (4.2%). At t0, 374 
patients had available results, of which 15 patients (4.0%) showed progression (3 FISH negative, 12 
FISH positive). Forest plots at different time points are provided in Supplemental figure 2. Due to 
insufficient numbers, no reliable conclusions could be drawn from this. 
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Subgroup analyses 
Subgroup analyses were performed for t0 and t2. At these time points all studies performed FISH 
tests. The following subgroups were predefined: age, gender, recurrent versus primary disease, 
presence of carcinoma in situ (CIS), prior BCG treatment, and BCG maintenance therapy versus BCG 
induction only. Patients with a positive FISH at t0 without CIS had a statistically significant (p=0.043) 
higher risk for developing recurrence compared to patients with CIS and a positive FISH (HR 1.32, 
95% CI: 0.91–1.91). No significant differences were found within the other subgroups, at either t0 or 
t2 (Figure 4).  
 
Discussion 
This IPD meta-analysis is the largest study evaluating FISH for predicting tumor recurrence and 
confirms that patients with a positive FISH test following BCG induction therapy have a higher risk for 
developing tumor recurrence during follow-up. The pooled analysis at t2 showed a HR of 3.70. This 
confirms the conclusion of all four included studies. Two included studies that evaluated the 
predictive value of FISH at t1, i.e. the end of the BCG induction therapy, reported inconsistent results, 
possibly due to low number of patients.
20,21
 Within the current pooled analysis, a positive FISH test at 
6 weeks is associated with a higher risk of recurrence during follow-up (HR 2.23). One of the included 
studies,
20
 as well as one of the studies for which IPD could not be obtained,
16
 reported that FISH had 
a predictive value for recurrence, when performed before BCG therapy was started (t0). However, 
this effect was not seen in the pooled analysis. A recently published study of Lotan et al. reported 
similar results for t1 and t2, but also reported a positive association at t0, in contrary to the current 
pooled analysis. 
22
 The HR of 23.44 at t3 seems high and promising, however the wide 95% CI (5.26–
104.49) makes this result unreliable. The results regarding FISH for predicting progression to muscle 
invasive disease should be interpreted with caution because of the limited number of events.   
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Subgroup analyses revealed a significant difference at t0 for presence of CIS. In patients 
without CIS, a positive FISH pre-BCG was associated with a higher risk of recurrence. For this group of 
patients, a positive FISH following TURBT might be suggestive for residual tumor. However, at t2 this 
difference was not seen anymore. A positive FISH at t2 may be related to an insufficient response to 
BCG. 
An overall false positive rate of FISH after BCG induction therapy of 41% seems high (Table 
4). However, it is possible that a median follow-up 1.5 years was too short to identify all future 
recurrences. Most recurrences occur within 5 years of initial BCG induction therapy, though 
recurrence after 10 years are not unusual.
23,24
 
Kamat et al. developed a CyPRIT-nomogram to predict BCG response based on changes in 
levels of a combination of nine cytokines in urine samples.
25
 Both the FISH test and CyPRIT-
nomogram identify a new group of patients, who show a molecular or cytokine failure, without 
clinical tumor present yet. This may assist in risk stratification and introduces the opportunity to offer 
these patients other subsequent treatment strategies at an earlier stage that hopefully will result in a 
better outcome. Treating all patients with a positive FISH test with a radical cystectomy may be too 
rigorous, but discussing clinical trials or changing BCG maintenance therapy to e.g. 
chemohyperthermia could be a viable option.
26,27
 When FISH is performed in patients treated with 
BCG, we recommend to perform FISH at 3 months, since this has the highest HR with the narrowest 
95% CI.  
A limitiation of this IPD meta-analysis is that for two studies no IPD could be obtained (79 
patients treated with BCG, mitomycin C or thiothepa). Also, the IPD of Lotan et al. could not be 
included in the current study since their publication is so recent, though all studies reported a higher 
risk for tumor recurrence in case of a positive FISH after BCG induction therapy. Another limitation of 
this analysis is that one study had a slightly different definition of a positive FISH test (Table 2). 
Though it is not likely that this would change the results of the present analysis, the more compliant 
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FISH criteria could have led to an overestimation of positive FISH tests. There was no uniform BCG 
maintenance protocol across the studies, which could also have influenced the risk of developing a 
recurrence.
28
 Furthermore, the impact of concurrent cytology findings could not be evaluated in this 
study since systematic cytology analyses were not available across the four trials. Taking the risk of 
bias across studies and statistical heterogeneity into account, our results should be interpreted with 
caution.  
Conclusion 
Patients with NMIBC and a positive FISH after BCG induction have a higher risk for developing tumor 
recurrence. When FISH is performed three months following initial TURBT, the predictive value of 
FISH is higher compared to the FISH immediately at the end of the induction course. Pre-BCG, FISH 
lacks a predictive value for predicting recurrence. FISH could assist urologists in risk stratification and 
counseling patients prone to recur after BCG therapy, preferably within clinical trials. 
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Table 1 Risk of bias according to the Quality in Prognosis Studies (QUIPS) tool 
 Mengual 
et al.[21] 
Savic et al. 
[23]  
Kamat et 
al. [24] 
Liem et al. 
[25] 
1. Study participation     
1) Adequate participation in the study by eligible persons Yes Partial  Yes Partial 
2) Description of the source population or population of 
interest 
Partial Yes Yes Yes 
3) Description of the baseline study sample Yes Yes Yes Yes 
4) Adequate description of the sampling frame and 
recruitment 
Yes Yes Yes Yes 
5) Adequate description of the period and place of 
recruitment 
Yes Yes Yes Yes 
6) Adequate description of inclusion and exclusion criteria Partial No Yes Yes 
The study sample adequately represents the population of 
interest 
Low risk of 
bias 
Moderate 
risk of bias 
Low risk of 
bias 
Low risk of 
bias 
2. Study attrition     
1) Adequate response rate for study participants Yes Unsure Yes Unsure 
2) Description of attempts to collect No No No Partial 
3) Reasons for loss to follow-up are provided No No No Partial 
4) Adequate description of participants lost to follow-up No No No Partial 
5) There are no important differences between participants 
who completed the study and those who did not 
No No No Partial 
The study data available adequately represent the study High risk 
of bias 
High risk 
of bias 
High risk 
of bias 
High risk 
of bias 
3. Prognostic factor measurement     
1) A clear definition or description of the prognostic factor is 
provided 
Yes Yes Yes Yes 
2) Method of prognostic factor measurement is adequately 
valid and reliable 
Yes Yes Yes Yes 
3) Continuous variables are reported or appropriate or 
appropriate cut points are used 
Yes Yes Yes Yes 
4) A clear definition of the outcome is provided Yes Yes Yes Yes 
5) Method of outcome measurement used is adequately valid 
and reliable 
Yes Yes Yes Yes 
6) Appropriate methods of imputation are used for missing 
prognostic factor data 
Yes Yes Yes Yes 
The prognostic factor is measured in a similar way for all 
participants 
Low risk of 
bias 
Low risk of 
bias 
Low risk of 
bias 
Low risk of 
bias 
4. Outcome measurement     
1) A clear definition of the outcome is provided Yes Yes Yes Yes 
2) Method of outcome measurement used is adequately valid 
and reliable 
Yes Yes Yes Yes 
3) The method and setting of outcome measurement is the 
same for all study participants 
Yes Yes Yes Yes 
The outcome of interest is measured in a similar way for all 
participants 
Low risk of 
bias 
Low risk of 
bias 
Low risk of 
bias 
Low risk of 
bias 
5. Study confounding     
1) All important confounders are measured No No Partial Yes 
2) Clear definitions of the important confounders measured 
are provided 
No No Partial Yes 
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3) Measurement of all important confounders is adequately 
valid and reliable 
No No Partial Yes 
4) The method and setting of confounding measurement are 
the same for all study participants 
No No Yes Partial 
5) Appropriate methods are used if imputation is used for 
missing confounder data 
NA NA NA NA 
6) Important potential confounders are accounted for in the 
study design 
No No Yes No 
7) Important potential confounders are accounted for in the 
analysis 
No No Partial Yes 
Important potential confounding factors are appropriately 
accounted for 
High risk 
of bias 
High risk 
of bias 
Moderate 
risk of bias 
Low risk of 
bias 
6. Statistical analysis and reporting     
1) Sufficient presentation of data to assess the adequacy of 
the analytic strategy 
Yes Yes Yes Yes 
2) Strategy for model building is appropriate and is based on 
a conceptual framework or model 
Yes Yes Yes Yes 
3) The selected statistical model is adequate for the design of 
the study 
Yes Yes Yes Yes 
4) There is no selective reporting of results Yes Yes Yes Yes 
The statistical analysis is appropriate, and all primary 
outcomes were reported 
Low risk of 
bias 
Low risk of 
bias 
Low risk of 
bias 
Low risk of 
bias 
NA = not applicable     
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Table 2 Characteristics of the included clinical trials. 
 Setting N Dates FISH Definition positive FISH Definition recurrence 
Mengual et 
al.[21] 
Single 
center, 
Spain 
65 Sept 2003 –  
      Oct 2004 
•Pre-BCG 
•Post-BCG, 3m 
 
100 cells scored, and one of the following criteria: 
• ≥5 cells aneuploidy of 2 or more chromosomes (chr. 3, 7 17) 
• ≥20 cells with a total loss of 9p21 
Histological proven 
bladder cancer 
Savic et al.[23] 7 Swiss 
centers 
68 Feb 2003 –  
      Feb 2006 
•Pre-BCG 
•Post-BCG, 3m 
25 cells scored, and one of the following criteria: 
• ≥4 cells aneuploidy of 2 or more chromosomes (chr. 3, 7 17) 
• ≥12 cells with a total loss of 9p21 
G3 cytology or 
histological proven 
bladder cancer 
Kamat et al.[24] Single 
center, 
USA 
126 June 2005 –  
      Feb 2012 
•Pre-BCG 
•Post-BCG, 6w 
•Post-BCG, 3m 
•Post-BCG, 6m 
25 cells scored, and one of the following criteria: 
• ≥4 cells aneuploidy of 2 or more chromosomes (chr. 3, 7 17) 
• ≥12 cells with a total loss of 9p21 
Histological proven 
bladder cancer 
Liem et al.[25] 5 Dutch 
centers 
114 Dec 2007 –  
      Jan 2013 
•Pre-BCG 
•Post-BCG, 6w 
•Post-BCG, 3m 
25 cells scored, and one of the following criteria: 
• ≥4 cells aneuploidy of 2 or more chromosomes (chr. 3, 7 17) 
• ≥12 cells with a total loss of 9p21 
Histological proven 
bladder cancer 
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Table 3 Baseline patient and tumour characteristics. 
 Total 
N=408 
Mengual et 
al.[21] 
N=65 
Savic et al.[23] 
N=68 
Kamat et al.[24] 
N=142 
Liem et al.[25] 
N=133 
Age (years), med [IQR] 70 [62-77] 72 [64-78] 73 [63.5-79.5] 67 [58-74] 71 [64-78] 
Gender, n (%) 
   Male 
   Female 
 
324 (79.4) 
84 (20.6) 
 
57 (87.7) 
8 (12.3) 
 
60 (88.2) 
8 (11.8) 
 
107 (75.4) 
35 (24.6) 
 
100 (75.2) 
33 (24.8) 
Follow-up (months), med [IQR] 18.8 [10.2-28.0] 14.1 [10.9-18.0] 17.9 [12.6-23.1] 26.4 [8.7-53.0] 23.3 [7.1-26.8] 
History of bladder cancer, n (%) 
   No 
   Yes 
   Missing 
 
194 (47.5) 
210 (51.5) 
4 (1.0) 
 
40 (61.5) 
25 (38.5) 
0 
 
35 (51.5) 
30 (44.1) 
3 (4.4) 
 
24 (16.9) 
118 (83.1) 
0 
 
95 (71.4) 
37 (27.8) 
1 (0.8) 
Prior BCG therapy, n (%) 
   No 
   Yes 
   Missing 
 
321 (78.7) 
77 (18.9) 
10 (2.4) 
 
58 (89.2) 
7 (10.8) 
0 
 
13 (19.1) 
51 (75.0) 
4 (5.9) 
 
130 (91.6) 
12 (8.4) 
0 
 
120 (90.2) 
7 (5.3) 
6 (4.5) 
Stage, n (%) 
   CIS only 
   Ta 
   T1 
   Missing 
 
72 (17.6)  
159 (39.0) 
166 (40.7) 
11 (2.7) 
 
11 (16.9) 
21 (32.3) 
22 (33.8) 
11 (17.0) 
 
31 (45.6) 
21 (30.9) 
16 (23.5) 
0 
 
7 (4.9) 
67 (47.2) 
68 (47.9) 
0 
 
23 (17.3) 
50 (37.6) 
60 (45.1) 
0 
Grade, n (%) 
   CIS only 
   G1 
   G2 
   G3 
   Missing 
 
72 (17.7) 
12 (2.9) 
75 (18.4) 
247 (60.5) 
2 (0.5) 
 
11 (16.9) 
4 (6.2) 
16 (24.6) 
32 (49.2) 
2 (3.1) 
 
31 (45.6) 
0 
10 (14.7) 
27 (39.7) 
0 
 
7 (4.9) 
2 (1.4) 
33 (23.3) 
100 (70.4) 
0 
 
23 (17.3) 
6 (4.5) 
16 (12.0) 
88 (66.2) 
0 
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CIS, n (%) 
   No 
   Yes 
   Missing 
 
236 (57.8) 
161 (39.5) 
11 (2.7) 
 
43 (66.2) 
11 (16.9) 
11 (16.9) 
 
26 (38.2) 
42 (61.8) 
0 
 
76 (53.5) 
66 (46.5) 
0 
 
91 (68.4) 
42 (31.6) 
0 
Risk group, n (%) 
   Low-/intermediate-risk 
   High-risk 
   Missing 
 
53 (13.0) 
344 (84.3) 
11 (2.7) 
 
10 (15.4) 
44 (67.7) 
11 (16.9) 
 
8 (11.8) 
60 (88.2) 
0 
 
23 (16.2) 
119 (83.8) 
0 
 
12 (9.0) 
121 (91.0) 
0 
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Table 4 Overview of number of recurrences and available FISH evaluations at different time points and their FISH result. 
 
  Pre-BCG 
(t0) 
 Post-BCG, 6 weeks 
(t1) 
 Post-BCG, 3 months 
(t2) 
 Post-BCG, 6 months 
(t3) 
  FISH - FISH +  FISH - FISH +  FISH - FISH +  FISH - FISH + 
Mengual et al.[21]   5/10 19/55     9/36 15/29    
Savic et al.[23]  4/20 14/30     10/48 12/20    
Kamat et al.[24]  9/39 39/95  16/72 33/64  9/54 31/49  4/49 15/22 
Liem et al.[25]  25/73 18/52  28/96 7/17  7/48 10/19    
Total  43/142 90/232  44/168 40/81  35/186 68/117  4/49 15/22 
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Table 5 Overview of FISH results and occurred conversions.  
 
 Patients  Recurrence 
All FISH negative 127 28 
All FISH positive 99 57 
FISH negative  FISH positive  
   Conversion between t0 – t1 
   Conversion between t0 – t2 
   Conversion between t1 – t2 
   Conversion between t2 – t3 
34 
   12 
   9 
   12 
   1 
19 
   8 
   6 
   5 
   0 
FISH positive  FISH negative 
   Conversion between t0 – t1 
   Conversion between t0 – t2 
   Conversion between t1 – t2 
   Conversion between t2 – t3 
126 
   58 
   49 
   14 
   5 
29 
   14 
   14 
   1 
   0 
Alternating FISH 
   FISH negative  positive  negative 
      - | + | - |  
      - | + | - | - 
        | - | + | - 
      - | - | + | - 
   FISH positive  negative  positive 
      + | - | + |  
      + | - | + | + 
      + | + | - | + 
   FISH positive  negative  positive  negative 
22 
 
   1 
   2 
   1 
   2 
 
   5 
   3 
   2 
   6 
8 
 
   0 
   0 
   0 
   0 
 
   4 
   1 
   1 
   2    
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